Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

These Analysts Revise Price Targets On Harmonic After Upbeat Q4 Results

Harmonic Inc. (NASDAQ: HLIT) reported better-than-expected Q4 results. Harmonic reported quarterly earnings of $0.17 per share, beating analysts’ estimates of $0.14 per share. The company’s quarterly sales came in at $164.33 million, versus expectations of $159.32 million.
byLisa Levin
January 31, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Harmonic Inc. (NASDAQ:HLIT) reported better-than-expected Q4 results.

Harmonic reported quarterly earnings of $0.17 per share, beating analysts’ estimates of $0.14 per share. The company’s quarterly sales came in at $164.33 million, versus expectations of $159.32 million.

The company said it sees FY23 GAAP earnings of $0.37 to $0.53 per share on revenue of $695 million to $735 million.

Harmonic shares dropped 7.2% to trade at $13.18 on Tuesday.

These analysts made changes to their price targets on Harmonic following the release of results.

  • Barclays raised the price target on Harmonic from $17 to $20. Barclays analyst Tim Long maintained an Overweight rating on the stock.
  • Raymond James cut the price target on Harmonic from $18 to $17. Raymond James analyst Simon Leopold maintained the stock with an Outperform.
  • Needham, meanwhile, maintained a $19 price target on the stock. Needham analyst Ryan Koontz reiterated the stock with a Buy.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

What’s Going On With Molecular Templates Stock?

By Erica Kollmann
April 9, 12:37 PM
Molecular Templates shares are volatile Tuesday after the company presented interim data from MT-6402 Phase I study in patients with PD-L1+ solid tumors. Molecular Templates said the findings show that MT-6402 acts uniquely from other approved checkpoint agents and was well-tolerated with no drug-related Grade 4 or Grade 5 adverse events observed. "We are excited to see objective responses in heavily pre-treated, checkpoint-experienced, head and neck cancer patients, a setting with high unmet medical need," said CEO Eric Poma.

MTEM